Apr. 15 at 5:11 AM
$RGNX Is anyone else tracking the job board? There’s a potential red flag here.
$RGNX is hiring Medical Science Liaisons (MSLs) for the DMD program, but the commercial sales force is nowhere to be found.
For a company supposedly "on track" for a BLA submission in a few months, this math doesn't add up. You don't launch a gene therapy with a skeleton crew.
Two theories:
The FDA Wall: Management doesn't actually believe the BLA will be granted or they're expecting a massive delay/CRL.
They’re hiring MSLs just to "bridge the gap" and keep the science talk alive.
The Buyout Play: They aren't hiring sales reps because they don't need them. AbbVie is either expanding the partnership to DMD or a full buyout is on the table for 2026.
Are these DMD job offers just "window dressing" to keep the stock afloat while the insiders look for the exit? Thoughts?
I don't see a powerful engagement from the regenxbio employees into rgx-202 . Feels like everyone is working on RGX-314..
